Toll-like Receptor 4 and Hepatic Fibrogenesis

 

 Buy Article Permissions and Reprints

ABSTRACT

Inflammation is strongly associated with chronic hepatic injury and the ensuing wound-healing process. Recent evidence from mouse models and human studies implicates Toll-like receptors (TLRs) as important regulators of the inflammatory response and a functional link between inflammation and fibrosis in the chronically injured liver. Here, we review mechanisms by which TLR4 and TLR4 ligands from the intestinal microbiota contribute to hepatic injury, inflammation, hepatic stellate cell activation, and fibrosis.

REFERENCES

• 1 Janeway Jr C A. Approaching the asymptote? Evolution and revolution in immunology.  Cold Spring Harb Symp Quant Biol. 1989;  54(Pt 1) 1-13
  CrossrefPubMedGoogle Scholar
• 2 Lemaitre B, Nicolas E, Michaut L, Reichhart J M, Hoffmann J A. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults.  Cell. 1996;  86 973-983
  CrossrefPubMedGoogle Scholar
• 3 Poltorak A, He X, Smirnova I et al.. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.  Science. 1998;  282 2085-2088
  CrossrefPubMedGoogle Scholar
• 4 O'Neill L A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress.  Immunol Rev. 2008;  226 10-18
  CrossrefPubMedGoogle Scholar
• 5 Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling.  Ann N Y Acad Sci. 2008;  1143 1-20
  CrossrefPubMedGoogle Scholar
• 6 Gay N J, Keith F J. Drosophila Toll and IL-1 receptor.  Nature. 1991;  351 355-356
  PubMedGoogle Scholar
• 7 Freudenberg M A, Tchaptchet S, Keck S et al.. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity.  Immunobiology. 2008;  213 193-203
  CrossrefPubMedGoogle Scholar
• 8 Kim H M, Park B S, Kim J I et al.. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.  Cell. 2007;  130 906-917
  CrossrefPubMedGoogle Scholar
• 9 Akira S, Takeda K. Toll-like receptor signalling.  Nat Rev Immunol. 2004;  4 499-511
  CrossrefPubMedGoogle Scholar
• 10 Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity.  Cell. 2006;  124 783-801
  CrossrefPubMedGoogle Scholar
• 11 Horng T, Barton G M, Flavell R A, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.  Nature. 2002;  420 329-333
  CrossrefPubMedGoogle Scholar
• 12 Yamamoto M, Sato S, Hemmi H et al.. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4.  Nature. 2002;  420 324-329
  CrossrefPubMedGoogle Scholar
• 13 Yamamoto M, Sato S, Hemmi H et al.. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway.  Nat Immunol. 2003;  4 1144-1150
  CrossrefPubMedGoogle Scholar
• 14 Pfeiffer R. Untersuchungen ušber das Choleragift.  Z Hygiene. 1892;  11 393-412
  PubMedGoogle Scholar
• 15 Alexander C, Rietschel E T. Bacterial lipopolysaccharides and innate immunity.  J Endotoxin Res. 2001;  7 167-202
  CrossrefPubMedGoogle Scholar
• 16 Jiang Z, Georgel P, Du X et al.. CD14 is required for MyD88-independent LPS signaling.  Nat Immunol. 2005;  6 565-570
  CrossrefPubMedGoogle Scholar
• 17 Huber M, Kalis C, Keck S et al.. R-form LPS, the master key to the activation ofTLR4/MD-2-positive cells.  Eur J Immunol. 2006;  36 701-711
  CrossrefPubMedGoogle Scholar
• 18 Beutler B. Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease.  Immunol Rev. 2007;  220 113-128
  CrossrefPubMedGoogle Scholar
• 19 Lotze M T, Zeh H J, Rubartelli A et al.. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity.  Immunol Rev. 2007;  220 60-81
  CrossrefPubMedGoogle Scholar
• 20 Kono H, Rock K L. How dying cells alert the immune system to danger.  Nat Rev Immunol. 2008;  8 279-289
  Google Scholar
• 21 Lee J Y, Zhao L, Youn H S et al.. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1.  J Biol Chem. 2004;  279 16971-16979
  CrossrefPubMedGoogle Scholar
• 22 Shi H, Kokoeva M V, Inouye K, Tzameli I, Yin H, Flier J S. TLR4 links innate immunity and fatty acid-induced insulin resistance.  J Clin Invest. 2006;  116 3015-3025
  CrossrefPubMedGoogle Scholar
• 23 Tsan M F, Baochong Gao. Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors.  J Endotoxin Res. 2007;  13 6-14
  CrossrefPubMedGoogle Scholar
• 24 Tsung A, Sahai R, Tanaka H et al.. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.  J Exp Med. 2005;  201 1135-1143
  CrossrefPubMedGoogle Scholar
• 25 Seki E, De Minicis S, Osterreicher C H et al.. TLR4 enhances TGF-beta signaling and hepatic fibrosis.  Nat Med. 2007;  13 1324-1332
  CrossrefPubMedGoogle Scholar
• 26 Bianchi M E, Manfredi A A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.  Immunol Rev. 2007;  220 35-46
  CrossrefPubMedGoogle Scholar
• 27 Lotze M T, Tracey K J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.  Nat Rev Immunol. 2005;  5 331-342
  CrossrefPubMedGoogle Scholar
• 28 Bonaldi T, Talamo F, Scaffidi P et al.. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.  EMBO J. 2003;  22 5551-5560
  CrossrefPubMedGoogle Scholar
• 29 Scaffidi P, Misteli T, Bianchi M E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.  Nature. 2002;  418 191-195
  CrossrefPubMedGoogle Scholar
• 30 Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin).  J Leukoc Biol. 2007;  81 49-58
  CrossrefPubMedGoogle Scholar
• 31 Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines.  J Immunol. 2008;  180 2531-2537
  CrossrefPubMedGoogle Scholar
• 32 Tian J, Avalos A M, Mao S Y et al.. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.  Nat Immunol. 2007;  8 487-496
  CrossrefPubMedGoogle Scholar
• 33 Youn J H, Oh Y J, Kim E S, Choi J E, Shin J S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes.  J Immunol. 2008;  180 5067-5074
  PubMedGoogle Scholar
• 34 Jiang D, Liang J, Noble P W. Hyaluronan in tissue injury and repair.  Annu Rev Cell Dev Biol. 2007;  23 435-461
  CrossrefPubMedGoogle Scholar
• 35 Jiang D, Liang J, Fan J et al.. Regulation of lung injury and repair by Toll-like receptors and hyaluronan.  Nat Med. 2005;  11 1173-1179
  CrossrefPubMedGoogle Scholar
• 36 Taylor K R, Trowbridge J M, Rudisill J A, Termeer C C, Simon J C, Gallo R L. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4.  J Biol Chem. 2004;  279 17079-17084
  CrossrefPubMedGoogle Scholar
• 37 Termeer C, Benedix F, Sleeman J et al.. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4.  J Exp Med. 2002;  195 99-111
  CrossrefPubMedGoogle Scholar
• 38 Nanji A A, Khettry U, Sadrzadeh S M. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease).  Proc Soc Exp Biol Med. 1994;  205 243-247
  CrossrefPubMedGoogle Scholar
• 39 Adachi Y, Moore L E, Bradford B U, Gao W, Thurman R G. Antibiotics prevent liver injury in rats following long-term exposure to ethanol.  Gastroenterology. 1995;  108 218-224
  CrossrefPubMedGoogle Scholar
• 40 Adachi Y, Bradford B U, Gao W, Bojes H K, Thurman R G. Inactivation of Kupffer cells prevents early alcohol-induced liver injury.  Hepatology. 1994;  20 453-460
  CrossrefPubMedGoogle Scholar
• 41 Li Z, Yang S, Lin H et al.. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.  Hepatology. 2003;  37 343-350
  CrossrefPubMedGoogle Scholar
• 42 Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff S C, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice.  Hepatology. 2009;  50 1094-1104
  CrossrefPubMedGoogle Scholar
• 43 Rivera C A, Bradford B U, Hunt K J et al.. Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine.  Am J Physiol Gastrointest Liver Physiol. 2001;  281 G200-G207
  PubMedGoogle Scholar
• 44 Duffield J S, Forbes S J, Constandinou C M et al.. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair.  J Clin Invest. 2005;  115 56-65
  CrossrefPubMedGoogle Scholar
• 45 Su G L, Klein R D, Aminlari A et al.. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4.  Hepatology. 2000;  31 932-936
  CrossrefPubMedGoogle Scholar
• 46 Seki E, Tsutsui H, Nakano H et al.. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta.  J Immunol. 2001;  166 2651-2657
  PubMedGoogle Scholar
• 47 Kopydlowski K M, Salkowski C A, Cody M J et al.. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo.  J Immunol. 1999;  163 1537-1544
  PubMedGoogle Scholar
• 48 Lichtman S N, Wang J, Lemasters J J. LPS receptor CD14 participates in release of TNF-alpha in RAW 264.7 and peritoneal cells but not in Kupffer cells.  Am J Physiol. 1998;  275(1 Pt 1) G39-G46
  PubMedGoogle Scholar
• 49 Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Büschenfelde K H, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge.  J Hepatol. 1995;  22 226-229
  CrossrefPubMedGoogle Scholar
• 50 Schuchmann M, Hermann F, Herkel J, van der Zee R, Galle P R, Lohse A W. HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells.  Immunol Lett. 2004;  93 199-204
  CrossrefPubMedGoogle Scholar
• 51 Van Bossuyt H, De Zanger R B, Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts.  J Hepatol. 1988;  7 325-337
  CrossrefPubMedGoogle Scholar
• 52 Fox E S, Thomas P, Broitman S A. Clearance of gut-derived endotoxins by the liver. Release and modification of 3H, 14C-lipopolysaccharide by isolated rat Kupffer cells.  Gastroenterology. 1989;  96(2 Pt 1) 456-461
  PubMedGoogle Scholar
• 53 Mimura Y, Sakisaka S, Harada M, Sata M, Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats.  Gastroenterology. 1995;  109 1969-1976
  CrossrefPubMedGoogle Scholar
• 54 Shao B, Lu M, Katz S C et al.. A host lipase detoxifies bacterial lipopolysaccharides in the liver and spleen.  J Biol Chem. 2007;  282 13726-13735
  CrossrefPubMedGoogle Scholar
• 55 Matsumura T, Degawa T, Takii T et al.. TRAF6-NF-kappaB pathway is essential for interleukin-1-induced TLR2 expression and its functional response to TLR2 ligand in murine hepatocytes.  Immunology. 2003;  109 127-136
  CrossrefPubMedGoogle Scholar
• 56 Matsumura T, Ito A, Takii T, Hayashi H, Onozaki K. Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes.  J Interferon Cytokine Res. 2000;  20 915-921
  CrossrefPubMedGoogle Scholar
• 57 Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.  Physiol Rev. 2008;  88 125-172
  CrossrefPubMedGoogle Scholar
• 58 Paik Y H, Schwabe R F, Bataller R, Russo M P, Jobin C, Brenner D A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.  Hepatology. 2003;  37 1043-1055
  CrossrefPubMedGoogle Scholar
• 59 Kao Y H, Jawan B, Goto S et al.. High-mobility group box 1 protein activates hepatic stellate cells in vitro.  Transplant Proc. 2008;  40 2704-2705
  CrossrefPubMedGoogle Scholar
• 60 Connolly M K, Bedrosian A S, Mallen-St Clair J et al.. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha.  J Clin Invest. 2009;  119 3213-3225
  PubMedGoogle Scholar
• 61 Chen X M, O'Hara S P, Nelson J B et al.. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB.  J Immunol. 2005;  175 7447-7456
  CrossrefPubMedGoogle Scholar
• 62 Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis.  Hepatology. 2005;  41 422-433
  CrossrefPubMedGoogle Scholar
• 63 Wells C L, Maddaus M A, Reynolds C M, Jechorek R P, Simmons R L. Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria.  Infect Immun. 1987;  55 2689-2694
  PubMedGoogle Scholar
• 64 Fukui H, Brauner B, Bode J C, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay.  J Hepatol. 1991;  12 162-169
  CrossrefPubMedGoogle Scholar
• 65 Parlesak A, Schäfer C, Schütz T, Bode J C, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease.  J Hepatol. 2000;  32 742-747
  CrossrefPubMedGoogle Scholar
• 66 Mathurin P, Deng Q G, Keshavarzian A, Choudhary S, Holmes E W, Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats.  Hepatology. 2000;  32 1008-1017
  CrossrefPubMedGoogle Scholar
• 67 Lin R S, Lee F Y, Lee S D et al.. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation.  J Hepatol. 1995;  22 165-172
  CrossrefPubMedGoogle Scholar
• 68 Rivera C A, Bradford B U, Seabra V, Thurman R G. Role of endotoxin in the hypermetabolic state after acute ethanol exposure.  Am J Physiol. 1998;  275(6 Pt 1) G1252-G1258
  PubMedGoogle Scholar
• 69 Steffen E K, Berg R D, Deitch E A. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node.  J Infect Dis. 1988;  157 1032-1038
  CrossrefPubMedGoogle Scholar
• 70 Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis.  Semin Liver Dis. 2008;  28 26-42
  Article in Thieme ConnectPubMedGoogle Scholar
• 71 Plebani M, Burlina A. Biochemical markers of hepatic fibrosis.  Clin Biochem. 1991;  24 219-239
  CrossrefPubMedGoogle Scholar
• 72 Bataller R, Brenner D A. Liver fibrosis.  J Clin Invest. 2005;  115 209-218
  CrossrefPubMedGoogle Scholar
• 73 Nolan J P, Leibowitz A I. Endotoxin and the liver. III. Modification of acute carbon tetrachloride injury by polymyxin b—an antiendotoxin.  Gastroenterology. 1978;  75 445-449
  PubMedGoogle Scholar
• 74 Grinko I, Geerts A, Wisse E. Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia.  J Hepatol. 1995;  23 449-458
  CrossrefPubMedGoogle Scholar
• 75 Chan C C, Hwang S J, Lee F Y et al.. Prognostic value of plasma endotoxin levels in patients with cirrhosis.  Scand J Gastroenterol. 1997;  32 942-946
  CrossrefPubMedGoogle Scholar
• 76 Luckey T D, Reyniers J A, Gyorgy P, Forbes M. Germfree animals and liver necrosis.  Ann N Y Acad Sci. 1954;  57 932-935
  CrossrefPubMedGoogle Scholar
• 77 Rutenburg A M, Sonnenblick E, Koven I, Aprahamian H A, Reiner L, Fine J. The role of intestinal bacteria in the development of dietary cirrhosis in rats.  J Exp Med. 1957;  106 1-14
  CrossrefPubMedGoogle Scholar
• 78 Isayama F, Hines I N, Kremer M et al.. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice.  Am J Physiol Gastrointest Liver Physiol. 2006;  290 G1318-G1328
  CrossrefPubMedGoogle Scholar
• 79 Poelstra K, Popov Y, Sverdlov D Y, Sharma A, Schuppan D. Gut-derived bacterial products drive progression of liver fibrosis in mdr2 − / − mice: Involvement of LPS and TLR4.  Hepatology. 2009;  50 819A
  PubMedGoogle Scholar
• 80 Watanabe A, Hashmi A, Gomes D A et al.. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9.  Hepatology. 2007;  46 1509-1518
  CrossrefPubMedGoogle Scholar
• 81 Gabele E, Muhlbauer M, Dorn C et al.. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis.  Biochem Biophys Res Commun. 2008;  376(2) 271-276
  CrossrefPubMedGoogle Scholar
• 82 Seki E, De Minicis S, Gwak G Y et al.. CCR1 and CCR5 promote hepatic fibrosis in mice.  J Clin Invest. 2009;  119 1858-1870
  PubMedGoogle Scholar
• 83 Huang H, Shiffman M L, Friedman S et al.. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C.  Hepatology. 2007;  46 297-306
  CrossrefPubMedGoogle Scholar
• 84 Li Y, Chang M, Abar O et al.. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection.  J Hepatol. 2009;  51 750-757
  CrossrefPubMedGoogle Scholar
• 85 Von Hahn T, Halangk J, Witt H et al.. Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease.  Scand J Gastroenterol. 2008;  43 584-592
  CrossrefPubMedGoogle Scholar
• 86 Guo J, Loke J, Zheng F et al.. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses.  Hepatology. 2009;  49 960-968
  CrossrefPubMedGoogle Scholar
• 87 Bjarnason I, Peters T J, Wise R J. The leaky gut of alcoholism: possible route of entry for toxic compounds.  Lancet. 1984;  1 179-182
  PubMedGoogle Scholar
• 88 Draper L R, Gyure L A, Hall J G, Robertson D. Effect of alcohol on the integrity of the intestinal epithelium.  Gut. 1983;  24 399-404
  CrossrefPubMedGoogle Scholar
• 89 Uesugi T, Froh M, Arteel G E, Bradford B U, Thurman R G. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice.  Hepatology. 2001;  34 101-108
  CrossrefPubMedGoogle Scholar
• 90 Hansen J, Cherwitz D L, Allen J I. The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats.  Hepatology. 1994;  20 461-474
  CrossrefPubMedGoogle Scholar
• 91 Hritz I, Mandrekar P, Velayudham A et al.. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88.  Hepatology. 2008;  48(4) 1224-1231
  CrossrefPubMedGoogle Scholar
• 92 Kono H, Rusyn I, Yin M et al.. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease.  J Clin Invest. 2000;  106 867-872
  CrossrefPubMedGoogle Scholar
• 93 Yang S Q, Lin H Z, Lane M D, Clemens M, Diehl A M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis.  Proc Natl Acad Sci U S A. 1997;  94 2557-2562
  CrossrefPubMedGoogle Scholar
• 94 Szabo G, Velayudham A, Romics Jr L, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4.  Alcohol Clin Exp Res. 2005;  29(11 Suppl) 140S-145S
  CrossrefPubMedGoogle Scholar
• 95 Rivera C A, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis.  J Hepatol. 2007;  47 571-579
  CrossrefPubMedGoogle Scholar
• 96 Cani P D, Amar J, Iglesias M A et al.. Metabolic endotoxemia initiates obesity and insulin resistance.  Diabetes. 2007;  56 1761-1772
  CrossrefPubMedGoogle Scholar
• 97 Cani P D, Bibiloni R, Knauf C et al.. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.  Diabetes. 2008;  57 1470-1481
  CrossrefPubMedGoogle Scholar
• 98 Cope K, Risby T, Diehl A M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis.  Gastroenterology. 2000;  119 1340-1347
  CrossrefPubMedGoogle Scholar
• 99 Nair S, Cope K, Risby T H, Diehl A M, Terence R H. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis.  Am J Gastroenterol. 2001;  96 1200-1204
  CrossrefPubMedGoogle Scholar
• 100 Adawi D, Kasravi F B, Molin G, Jeppsson B. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat.  Hepatology. 1997;  25 642-647
  CrossrefPubMedGoogle Scholar
• 101 Ewaschuk J, Endersby R, Thiel D et al.. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis.  Hepatology. 2007;  46 841-850
  CrossrefPubMedGoogle Scholar
• 102 Osman N, Adawi D, Ahrné S, Jeppsson B, Molin G. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry.  Dig Liver Dis. 2007;  39 849-856
  CrossrefPubMedGoogle Scholar
• 103 Liu Q, Duan Z P, Ha D K, Bengmark S, Kurtovic J, Riordan S M. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.  Hepatology. 2004;  39 1441-1449
  CrossrefPubMedGoogle Scholar
• 104 Rayes N, Seehofer D, Hansen S et al.. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients.  Transplantation. 2002;  74 123-127
  CrossrefPubMedGoogle Scholar
• 105 Rayes N, Seehofer D, Theruvath T et al.. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation—a randomized, double-blind trial.  Am J Transplant. 2005;  5 125-130
  CrossrefPubMedGoogle Scholar
• 106 Loguercio C, Federico A, Tuccillo C et al.. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.  J Clin Gastroenterol. 2005;  39 540-543
  CrossrefPubMedGoogle Scholar
• 107 Velayudham A, Dolganiuc A, Ellis M et al.. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.  Hepatology. 2009;  49 989-997
  CrossrefPubMedGoogle Scholar
• 108 Runyon B A, Borzio M, Young S, Squier S U, Guarner C, Runyon M A. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis.  Hepatology. 1995;  21 1719-1724
  PubMedGoogle Scholar
• 109 Llovet J M, Bartolí R, Planas R et al.. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock.  Hepatology. 1996;  23 781-787
  CrossrefPubMedGoogle Scholar
• 110 Bauer T M, Fernández J, Navasa M, Vila J, Rodés J. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis.  J Hepatol. 2002;  36 501-506
  CrossrefPubMedGoogle Scholar
• 111 Fernández J, Navasa M, Planas R et al.. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.  Gastroenterology. 2007;  133 818-824
  CrossrefPubMedGoogle Scholar
• 112 Runyon B A. A pill a day can improve survival in patients with advanced cirrhosis.  Gastroenterology. 2007;  133 1029-1031
  CrossrefPubMedGoogle Scholar
• 113 Mullarkey M, Rose J R, Bristol J et al.. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.  J Pharmacol Exp Ther. 2003;  304 1093-1102
  CrossrefPubMedGoogle Scholar
• 114 Rossignol D P, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.  J Endotoxin Res. 2002;  8 483-488
  PubMedGoogle Scholar
• 115 Fort M M, Mozaffarian A, Stöver A G et al.. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.  J Immunol. 2005;  174 6416-6423
  PubMedGoogle Scholar
• 116 Ii M, Matsunaga N, Hazeki K et al.. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.  Mol Pharmacol. 2006;  69 1288-1295
  CrossrefPubMedGoogle Scholar
• 117 Kawamoto T, Ii M, Kitazaki T, Iizawa Y, Kimura H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain.  Eur J Pharmacol. 2008;  584 40-48
  CrossrefPubMedGoogle Scholar
• 118 Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model.  Eur J Pharmacol. 2007;  571 231-239
  CrossrefPubMedGoogle Scholar
• 119 Schnabl B, Brandl K, Fink M et al.. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells.  Biochem Biophys Res Commun. 2008;  375 210-214
  CrossrefPubMedGoogle Scholar
• 120 Kanzler H, Barrat F J, Hessel E M, Coffman R L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.  Nat Med. 2007;  13 552-559
  CrossrefPubMedGoogle Scholar

Robert F SchwabeM.D. 

Russ Berrie Pavilion, Room 415, 1150 Street, Nicholas Avenue

New York, NY 10032

Email: rfs2102@columbia.edu